Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-22-020820
Filing Date
2022-05-26
Accepted
2022-05-26 17:00:17
Documents
2

Document Format Files

Seq Description Document Type Size
1 DEFA14A ny20004344x1_defa14a.htm DEFA14A 33812
2 logo_biocryst2a.jpg GRAPHIC 30535
  Complete submission text file 0001140361-22-020820.txt   76723
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-23186 | Film No.: 22971072
SIC: 2836 Biological Products, (No Diagnostic Substances)